"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A 32-year-old man developed gastroparesis after taking tirzepatide for weight loss, which isn't approved in India. Doctors ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Topline results from our Phase 2 BMT-801 'signal detection' clinical study with MC4R agonist bremelanotide plus a glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist ...

These receptors are known as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Together, they work to control blood sugar levels and reduce appetite. In contrast ...

A new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...

Users of weight-loss medications like Ozempic and Tirzepatide are going blind, according to a new study. The study, published in JAMA Opthalmology, reports multiple cases of serious eye complications ...